Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Effect of parity and ß-amyloid on cognition and hippocampal volume in postmenopausal women

  • Gallay, Clara
  • Soldevila-Domenech, Natalia
  • López-Martos, David
  • Sánchez Benavides, Gonzalo
  • Huguet, Jordi
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Sundermann, Erin E.
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD pathology on brain and cognitive aging. We examined the effect of parity and AD pathology on hippocampal volume (HV) and cognitive changes in cognitively unimpaired (CU) postmenopausal women. Methods: Analysis was performed on CU postmenopausal women from the ALFA+ observational cohort based in the BarcelonaBeta Brain research center, who completed 1 or 2 visits spaced by ∼3 years (mean = 3.38, SD = 0.55) with reproductive data, cognitive testing (modified Preclinical Alzheimer's Cognitive Composite), CSF biomarkers (Aβ42 and Aβ40), and structural MRI. We used linear mixed-effects models to investigate the interactive effects of parity, time, and Aβ status (based on CSF Aβ42/Aβ40) on cognition and HV. APOE-ε4 status, age, and total intracranial volume were included as covariates. Results: A total of 254 women were included in our analyses ranging from 49.2 to 73.4 years (mean age = 61.2) at visit 1. A significant interaction between parity and Aβ status was observed for cognitive decline and HV. In women with positive amyloid status, higher parity was associated with steeper cognitive decline (β = -0.035, 95% CI -0.068 to -0.003, p = 0.033) and lower HV across time points (β = -0.134, 95% CI -0.263 to -0.005, p = 0.036). Discussion: In CU postmenopausal women, higher parity interacts with AD pathology to influence cognitive decline and HV reductions. These findings suggest that parity may affect resilience to AD pathology in preclinical AD stages., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant 2021 SGR 00913. C. Gallay is supported by the Alzheimer Association Clinician Scientist Fellowship grant (AACSF-23-1145154). G. Sanchez-Benavides receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. M. Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, from a fellowship from “la Caixa” Foundation (ID 100010434), and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 847648. J. Domingo-Jispert has received research support from the EU/EFPIA Innovative Medicines Initiative JointUndertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). G. Salvado received funding from the European Union's Horizon 2020 Research and Innovation Program under 503 Marie Sklodowska-Curie action grant agreement number 101061836, an Alzheimer's Association Research 504 Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, 505 AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research 506 Area MultiPark (Multidisciplinary Research in Parkinson's Disease) at Lund University. E. Sundermann receives funding from the NIH (5R01AG074221). O. Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). A. Brugulat-Serrat receives funding from the Alzheimer Association Clinician Scientist Fellowship (AACSF-23-1145154).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease

  • Salvadó, Gemma
  • Gispert, Juan Domingo
  • Suárez-Calvet, Marc
  • Hansson, Oskar
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, setting, and participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main outcome and measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ε4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P = .12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P < .001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P < .001). Conclusions and relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test-or when used in a sequential 2-step approach alongside PET or CSF testing-as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments., Work at the authors’ research center (Lund University) was supported by the National Institute of Aging (R01AG083740), European Research Council (ADG-101096455), Alzheimer’s Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775 and 2018-02052, 2021-02219), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University, Swedish Alzheimer Foundation (AF-980907, AF-994229), Swedish Brain Foundation (FO2021-0293, FO2023-0163), Parkinson Foundation of Sweden (1412/22), Cure Alzheimer’s Fund, Rönström Family Foundation, Berg Family Foundation, Greta och Johan Kock Foundation, WASP and DDLS joint call for research projects (WASP/DDLS22-066), Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259), Bundy Academy at Lund University (2025-2026-2024-2428) and the Swedish federal government under the ALF agreement (2022-Projekt0080, 2022-Projekt0107). Dr Salvadó received funding from the European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie action grant agreement number 101061836, an Alzheimer’s Association Research Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research Area MultiPark (multidisciplinary research in Parkinson’s disease) at Lund University. This study was also funded by the Instituto de Salud Carlos III (Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España) through the projects INT21/00073, PI20/01473 and PI23/01786 to Dr Fortea) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa, and cofunded by the European Regional Development Fund/European Social Fund. This work was also supported by National Institutes of Health grants R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394, and R61AG066543 to Dr Fortea. It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151 to Dr Fortea) and Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020 to Dr Fortea). Dr Suárez-Calvet received funding from the European Research Council under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III and cofunded by the European Union; and from a fellowship from la Caixa Foundation (100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). The Translational Biomarkers in Aging and Dementia cohort is supported by the Weston Brain Institute, Canadian Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815 and 162303), Canadian Consortium of Neurodegeneration and Aging (MOP-11-51-31-team 1), the Alzheimer’s Association (NIRG-12-92090 and NIRP-12-259245), Brain Canada Foundation (CFI Project 34874; 33397), the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314) and the Colin J. Adair Charitable Foundation. The Wisconsin Registry for Alzheimer's Prevention cohort was supported by R01AG027161, R01AG021155 and P30AG062715 from SC Johnson. The Australian Imaging Biomarkers and Lifestyle Study of Ageing study is funded by the Commonwealth Scientific and Industrial Research Organization, and the National Health and Medical Research Council. The Sant Pau Initiative on Neurodegeneration cohort received funding from the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI19/00882, PI18/00435, PI22/00611, INT19/00016, INT23/00048, PI17/01896, and AC19/00103), and the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas program, jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. The Sant Pau Initiative on Neurodegeneration cohort was also supported by the National Institutes of Health (grants 1R01AG056850-01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408), Marató TV3 Foundation grants 20141210, 044412 and 20142610, a grant from the Fundació Bancaria La Caixa (Down Alzheimer Barcelona Neuroimaging Initiative project), Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas. Horizon 21 Consortium is partly funded by Jérôme Lejeune Foundation. PREVENT-AD was launched in 2011 as a $13.5 million, 7-year public-private partnership using funds provided by McGill University, the Fonds de Recherche du Québec–Santé, an unrestricted research grant from Pfizer Canada, the J.L. Levesque Foundation, the Lemaire Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Additional funding sources include the Canadian Institutes of Health Research (438655), US National Institutes of Health (R01 AG068563), Alzheimer’s Association, Alzheimer Society of Canada and Brain Canada grants. Dr Blennow is supported by the Swedish Research Council (2017-00915 and 2022-00732), the Swedish Alzheimer Foundation (AF-930351, AF-939721, AF-968270, and AF-994551), Hjärnfonden, Sweden (ALZ2022-0006 and FO2024-0048-TK-130), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG-965240 and ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer, the Kirsten and Freddy Johansen Foundation, and Familjen Rönströms Stiftelse. Dr Teunissen is supported by the European Commission (Marie Curie International Training Network, grant agreement 860197) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking, grant 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, cofinanced from the European Union’s Horizon Europe Research and Innovation Programme and by the participating states (22HLT07 NEuroBioStand). The CANTATE project was funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, the Dutch Research Council, Alzheimer Drug Discovery Foundation, the Selfridges Group Foundation, and Alzheimer Netherlands. Dr Teunissen is also a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (73305095007) and Health~Holland, Topsector Life Sciences & Health (LSHM20106), and of TAP-dementia, a ZonMw-funded project (10510032120003) in the context of the Dutch National Dementia Strategy.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Effect of parity and ß-amyloid on cognition and hippocampal volume in postmenopausal women

  • Gallay, Clara
  • Soldevila-Domenech, Natalia
  • López-Martos, David
  • Sánchez Benavides, Gonzalo
  • Huguet, Jordi
  • Suárez-Calvet, Marc
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Sundermann, Erin E.
  • Grau, Oriol (Grau Rivera)
  • Brugulat Serrat, Anna, 1986-
  • ALFA Study
Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD pathology on brain and cognitive aging. We examined the effect of parity and AD pathology on hippocampal volume (HV) and cognitive changes in cognitively unimpaired (CU) postmenopausal women. Methods: Analysis was performed on CU postmenopausal women from the ALFA+ observational cohort based in the BarcelonaBeta Brain research center, who completed 1 or 2 visits spaced by ∼3 years (mean = 3.38, SD = 0.55) with reproductive data, cognitive testing (modified Preclinical Alzheimer's Cognitive Composite), CSF biomarkers (Aβ42 and Aβ40), and structural MRI. We used linear mixed-effects models to investigate the interactive effects of parity, time, and Aβ status (based on CSF Aβ42/Aβ40) on cognition and HV. APOE-ε4 status, age, and total intracranial volume were included as covariates. Results: A total of 254 women were included in our analyses ranging from 49.2 to 73.4 years (mean age = 61.2) at visit 1. A significant interaction between parity and Aβ status was observed for cognitive decline and HV. In women with positive amyloid status, higher parity was associated with steeper cognitive decline (β = -0.035, 95% CI -0.068 to -0.003, p = 0.033) and lower HV across time points (β = -0.134, 95% CI -0.263 to -0.005, p = 0.036). Discussion: In CU postmenopausal women, higher parity interacts with AD pathology to influence cognitive decline and HV reductions. These findings suggest that parity may affect resilience to AD pathology in preclinical AD stages., The research leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant 2021 SGR 00913. C. Gallay is supported by the Alzheimer Association Clinician Scientist Fellowship grant (AACSF-23-1145154). G. Sanchez-Benavides receives funding from the Ministerio de Ciencia e Innovacion, Spanish Research Agency, PID2020-119556RA-I00. M. Suárez-Calvet receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 Research and Innovation Programme (grant agreement 948677), Project “PI19/00155,” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, from a fellowship from “la Caixa” Foundation (ID 100010434), and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement 847648. J. Domingo-Jispert has received research support from the EU/EFPIA Innovative Medicines Initiative JointUndertaking AMYPAD (grant agreement 115952), EIT Digital (Grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261). G. Salvado received funding from the European Union's Horizon 2020 Research and Innovation Program under 503 Marie Sklodowska-Curie action grant agreement number 101061836, an Alzheimer's Association Research 504 Fellowship (AARF-22-972612), the Brightfocus Foundation (A2024007F), the Alzheimerfonden (AF-980942, 505 AF-994514, AF-1012218), Greta och Johan Kocks research grants and travel grants from the Strategic Research 506 Area MultiPark (Multidisciplinary Research in Parkinson's Disease) at Lund University. E. Sundermann receives funding from the NIH (5R01AG074221). O. Grau-Rivera receives funding from the Alzheimer's Association Research Fellowship Program (2019-AARF-644568), from Instituto de Salud Carlos III (PI19/00117) and from the Spanish Ministry of Science Innovation and Universities (Juan de la Cierva programme IJC2020-043417-I). A. Brugulat-Serrat receives funding from the Alzheimer Association Clinician Scientist Fellowship (AACSF-23-1145154).